Head and Neck Squamous Cell Carcinoma
📧 Sign up to get email alerts when something new happens for Head and Neck Squamous Cell Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-08-17Clinical Trial Results: Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma [Phase 1, Phase 2]
Phase 1/2 trial evaluating ramucirumab plus pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma has been completed w…
-
CLINICAL_TRIALS trial_result · 2026-07-23Clinical Trial Results: NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours [Phase 1, Phase 2]
Phase 1/2 trial results of NUC-3373 in combination with other agents in patients with advanced solid tumors; study status terminated with re…
-
CLINICAL_TRIALS trial_result · 2026-07-14Clinical Trial Update: A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma [Phase 3]
A Phase 3 trial comparing RPH-002 with Erbitux in unresectable metastatic or recurrent head and neck squamous cell carcinoma has completed.
-
CLINICAL_TRIALS trial_result · 2026-06-03Clinical Trial Update: Testing the Use of Investigational Drugs Atezolizumab and/or Bevacizumab With or Without Standard Chemotherapy in the Second-Line Treatment of Advanced-Stage Head and Neck Cancers [Phase 2, Phase 3]
Phase 2/3 trial evaluating atezolizumab and/or bevacizumab with or without standard chemotherapy as second-line treatment for advanced head …
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment [Phase 3]
Phase 3 clinical trial evaluating adding cetuximab to pembrolizumab-based therapy for metastatic or recurrent head and neck squamous cell ca…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2026-04-27Clinical Trial Update: JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC [Phase 3]
Phase 3 trial evaluating JNJ-90301900 (NBTXR3) activated by radiotherapy with or without cetuximab in locally advanced head and neck squamou…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC [Phase 2]
Phase 2 trial assessing induction and adjuvant camrelizumab with chemoradiation for locally advanced head and neck squamous cell carcinoma h…
-
CLINICAL_TRIALS trial_result · 2026-04-24Clinical Trial Update: Atezolizumab and Bevacizumab in Patients With Recurrent or Metastatic Squamous-cell Carcinoma of the Head and Neck [Phase 2]
A Phase 2 trial evaluating the combination of atezolizumab and bevacizumab in recurrent or metastatic head and neck squamous cell carcinoma …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies [Phase 2]
Phase 2 clinical trial evaluating a PD-1–blocking monoclonal antibody in combination with a metabolic modulator for several solid tumors is …
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Clinical Study of GT201 in Combination With PD-1 Inhibitor for Advanced Head and Neck Tumors [NA]
Grit Biotechnology is conducting a clinical trial to assess GT201 in combination with a PD-1 inhibitor for advanced head and neck squamous c…
-
CLINICAL_TRIALS research · 2026-04-24Clinical Trial Update: Neoadjuvant Treatment of Locally Advanced HNSCC With Pertuzumab Combined With Lenvatinib. [Phase 2]
Phase 2 neoadjuvant trial combining pertuzumab with lenvatinib for locally advanced head and neck squamous cell carcinoma; enrollment is cur…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Neoadjuvant Chemotherapy and Programmed Cell Death Protein 1(PD-1) Inhibition for Head and Neck Cancer Treatment De-escalation (NeoScorch HN) [Phase 2]
A Phase 2 trial assesses neoadjuvant chemotherapy combined with a PD-1 inhibitor for head and neck squamous cell carcinoma with the goal of …
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: A Clinical Trial of PF-08046037 Alone or With Sasanlimab in Patients With Advanced or Metastatic Malignancies [Phase 1]
Pfizer's Phase 1 trial of PF-08046037 alone or with sasanlimab in advanced cancers has been terminated.
-
CLINICAL_TRIALS other · 2026-04-23Clinical Trial Update: Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab [Phase 1]
A Phase 1 study evaluating a personalized neoantigen dose-adjusted vaccine in combination with pembrolizumab for squamous cell cancers of th…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer [Phase 2]
This Phase 2 clinical trial is evaluating BMX-001 as a radioprotector added to standard chemoradiation therapy for head and neck cancers and…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or Radiation [NA]
A clinical trial update describes remote audiometry being studied to monitor treatment-related hearing loss in patients with head and neck s…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors [Phase 1, Phase 2]
A Phase 1/2 clinical trial of GTAEXS617 in adults with advanced solid tumors is currently recruiting. The study encompasses head and neck sq…
-
CLINICAL_TRIALS research · 2026-04-23Clinical Trial Update: A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors [Phase 1, Phase 2]
AstraZeneca is conducting a Phase 1/2 trial to evaluate the safety of AZD6750 in adults with select advanced or metastatic solid tumors; the…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Pembrolizumab, INCB081776, and Radiation Therapy for Head and Neck Squamous Cell Carcinoma [EARLY_Phase 1]
An early-phase 1 clinical trial update evaluating pembrolizumab in combination with INCB081776 and radiation therapy for head and neck squam…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer [Phase 2]
This clinical trial update describes a Phase 2 study evaluating the safety and tolerability of Nivolumab alone or in combination with Relatl…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Diagnostic Performance Of 4D Dynamic LAFOV FDG-PET Acquisition for Differentiation of Residual Disease and Post-radiation Inflammation in Head Neck SCC Treated by Radiotherapy.
A clinical trial evaluating a 4D dynamic LAFOV FDG-PET protocol to distinguish residual disease from post-radiation inflammation in head and…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1) [Phase 3]
Phase 3 clinical trial update: Merus B.V. is evaluating Petosemtamab in combination with pembrolizumab versus pembrolizumab alone as first-l…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Oropharynx (OPX) Biomarker Trial
Mayo Clinic is conducting a biomarker-focused clinical trial in patients with HPV-positive and HPV-negative oropharyngeal cancer across stag…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: Re-radiotherapy Combined With Chidamide for the Treatment of Recurrent Head and Neck Squamous Cell Carcinoma After Radiotherapy [Phase 1]
A Phase 1 clinical trial is evaluating re-radiotherapy combined with chidamide for recurrent head and neck squamous cell carcinoma after pri…
-
CLINICAL_TRIALS research · 2026-04-22Clinical Trial Update: A Study Investigating the Efficacy and Safety of the Combination of Iparomlimab and Tuvonralimab With or Without Chemotherapy in Second-line and Subsequent Treatments for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma [NA]
An ongoing clinical trial is evaluating the combination of iparomlimab and tuvonralimab, with or without chemotherapy, for second-line and s…